Dianthus Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
54.8M
on 2026-06-30, from 29.3M on 2024-03-31 10-Q ↗
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-09-18. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗
$500.0M
TD Securities (USA), agreement of 2026-09-18. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-04 is not read yet.
Cash
22.8 quarters
$886.8M on 2026-06-30 ÷ $38.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-03-11 | Public offering incl. 0.40M pre-funded | 7,716,050 | $81.00 | $625.0M | 424B5 ↗ |
| 2025-09-11 | Public offering incl. 1.11M pre-funded | 7,600,000 | $33.00 | $250.8M | 424B5 ↗ |